Systematic integration of biomedical knowledge prioritizes drugs for repurposing

Author:

Himmelstein Daniel Scott12ORCID,Lizee Antoine34,Hessler Christine3,Brueggeman Leo35,Chen Sabrina L36,Hadley Dexter78,Green Ari3,Khankhanian Pouya39,Baranzini Sergio E13ORCID

Affiliation:

1. Biological and Medical Informatics Program, University of California, San Francisco, San Francisco, United States

2. Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia, United States

3. Department of Neurology, University of California, San Francisco, San Francisco, United States

4. ITUN-CRTI-UMR 1064 Inserm, University of Nantes, Nantes, France

5. University of Iowa, Iowa City, United States

6. Johns Hopkins University, Baltimore, United States

7. Department of Pediatrics, University of California, San Fransisco, San Fransisco, United States

8. Institute for Computational Health Sciences, University of California, San Francisco, San Francisco, United States

9. Center for Neuroengineering and Therapeutics, University of Pennsylvania, Philadelphia, United States

Abstract

The ability to computationally predict whether a compound treats a disease would improve the economy and success rate of drug approval. This study describes Project Rephetio to systematically model drug efficacy based on 755 existing treatments. First, we constructed Hetionet (neo4j.het.io), an integrative network encoding knowledge from millions of biomedical studies. Hetionet v1.0 consists of 47,031 nodes of 11 types and 2,250,197 relationships of 24 types. Data were integrated from 29 public resources to connect compounds, diseases, genes, anatomies, pathways, biological processes, molecular functions, cellular components, pharmacologic classes, side effects, and symptoms. Next, we identified network patterns that distinguish treatments from non-treatments. Then, we predicted the probability of treatment for 209,168 compound–disease pairs (het.io/repurpose). Our predictions validated on two external sets of treatment and provided pharmacological insights on epilepsy, suggesting they will help prioritize drug repurposing candidates. This study was entirely open and received realtime feedback from 40 community members.

Funder

National Science Foundation

Heidrich Family and Friends Foundation

National Institutes of Health

National Cancer Institute

U.S. National Library of Medicine

Publisher

eLife Sciences Publications, Ltd

Subject

General Immunology and Microbiology,General Biochemistry, Genetics and Molecular Biology,General Medicine,General Neuroscience

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3